Review Article

PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis

Lina Sabatino, Alessandra Fucci, Massimo Pancione, and Vittorio Colantuoni

Department of Biological, Geological and Environmental Sciences, University of Sannio, via Port’Arsa 11, 82100 Benevento, Italy

Correspondence should be addressed to Vittorio Colantuoni, vittorio.colantuoni@gmail.com

Received 27 February 2012; Accepted 21 April 2012

1. Introduction

Peroxisome proliferator activated receptors (PPARs) are ligand-dependent transcription factors belonging to the nuclear receptor superfamily. Three PPAR isotypes have been identified so far: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3), each displaying a tissue specific expression pattern. PPARα is predominantly expressed in liver, brown adipose tissue, skeletal muscle, endothelium, and heart; PPARβ/δ has a broader expression pattern; PPARγ is expressed in adipose tissue, muscle, gastrointestinal tract, blood cells, macrophages, and liver [1–3]. PPARs form permissive heterodimers with the retinoid X receptors (RXR) and recognize specific sequence motifs, defined PPRE (Peroxisome proliferator response elements), in the regulatory regions of target genes [3–6]. In the absence of ligand, PPARs are complexed with corepressor proteins such as NCoR (nuclear receptor corepressor) or SMRT (silencing mediator of retinoid and thyroid receptors) and act as transcriptional repressors. Ligand binding induces conformational changes that allow displacement of the corepressor complexes and recruitment of transcriptional coactivators. These include members of the steroid receptor coactivator (SRC) family and histone acetyltransferases, such as p300/CBP, that modify the chromatin structure at PPRE-containing promoters, affecting gene transcription [3, 7]. A variety of endogenous and exogenous compounds, including lipophilic molecules such as polyunsaturated fatty acids, prostaglandines, leukotrienes, and hypolipidemic drugs, have been identified as PPAR ligands. The structural heterogeneity of these ligands seems to reflect the conformation of the ligand binding domain (LBD), which forms a large Y-shaped hydrophobic pocket with relatively low ligand specificity [8].

PPARs modulate cellular and whole-body glucose and lipid homeostasis. Upon activation by the synthetic agonists fenofibrate and gemfibrozil, PPARα stimulates hepatic lipid uptake and catabolism displaying antiatherosclerotic and hypolipidemic effects. PPARγ is activated by the antidiabetic agents thiazolidinediones (TZDs) and increases insulin sensitivity in adipose and muscle tissues. Genetic and pharmacological studies have revealed important roles of PPARβ/δ in regulating lipid metabolism and energy homeostasis [8, 9]. In addition to their metabolic effects, PPARs...
have also been implicated in the modulation of immune and inflammatory processes, vascular homeostasis, tissue remodeling, cell differentiation, and proliferation both in normal and neoplastic tissues (Figure 1) [10–16]. In recent years, several studies have addressed the role of PPARs in cancer development. PPARα has shown tumor-promoting effects in rodents inducing hepatocarcinoma formation. Its role in humans is less clear but its activation by exogenous agonists causes inhibition of tumor cell growth in cell lines derived from different tumors [16–20]. Conflicting data have suggested a role for PPARβ/δ either as a tumor suppressor or as a tumor promotor [21–24]. Finally, a large body of evidence supports PPARγ involvement in tumor development.

2. PPARγ Structure and Function

PPARG is located on human chromosome 3p25.2, spans a region of 100 Kb in length, and is organized in nine exons. Four major transcriptional start sites have been identified and, by differential promoter usage and alternative splicing, four mature mRNAs are generated differing in their 5’ end. Three transcripts, PPARγ1, 3, and 4, produce the identical protein PPARγ1. PPARγ2 transcript, in contrast, uses a different translational start codon and synthesizes PPARγ2 with 28 additional amino acids at the N-terminus (Figure 2) [25–29]. The mature protein shares the same overall structure of all nuclear receptors. The A/B region at the N-terminus is the most variable in length and sequence and is the key determinant of isotype-selective gene expression and function [30]. It contains the ligand-independent transactivation domain AF1, (residues 1–71 of PPARγ1) the lysine 79 and serine 84 residues, targets of SUMOylation, and phosphorylation events, respectively, that negatively regulate receptor activity [31]. The C region is the DNA binding domain, characterized by two C4 zinc-finger motifs, that interact with the major groove of the DNA. The D or hinge region allows receptor dimerization and DNA binding. The E/F region is the ligand binding domain (LBD) constituted by 12 α helices where the agonist accommodates. Ligand addition induces structural changes in the LBD that enable coactivators release and coactivators recruitment, mainly through the AF2 domain in helix 12, entitling ligand-dependent transactivation [32, 33]. PPARγ1 and y2 isoforms have a cell-specific expression pattern, although the functional differences have not been completely elucidated [34]. PPARγ2 expression is restricted to adipose tissue, where it acts as a master transcription factor in adipogenesis: in vitro it promotes adipocyte differentiation, while in vivo it lowers circulating NEFA and improves whole-body insulin sensitivity [35]. PPARγ1 is more broadly expressed; it is abundant in adipose tissue, macrophages, and gastrointestinal epithelium where it cooperates with the transcription factor Hic5 to promote epithelial cells differentiation during embryonic development [34, 36–38]. This observation suggests that PPARγ is involved in the differentiation of several epithelia, including colon epithelium.

Regulation of gene expression by PPARγ occurs through distinct mechanisms. In the absence of agonists, the PPARγ/

| Tumor type       | Supposed function                        | References |
|------------------|------------------------------------------|------------|
| Colon cancer     | Associated with good patients’ prognosis | [105, 106] |
| Hepatic cancer   | Protective effect against cancer          | [59]       |
| Renal cell carcinoma | Potential target of pharmacological therapy | [45]       |
| Prostate cancer  | Potential target of pharmacological therapy | [45]       |
| Ovarian cancer   | Protective effect against cancer          | [46]       |
| B cell lymphoma  | Potential target of pharmacological therapy | [104]       |
| Ependymoma       | Not defined                               | [143]      |
| Breast cancer    | Protective effect against cancer          | [47, 50, 51] |
| Neuroblastoma    | Protective effect against cancer          | [52]       |
| Pancreatic Cancer | Associated with shorter overall survival  | [77]       |
| Thyroid carcinoma| Protective effect against cancer          | [48]       |
| Liposarcoma      | Induction of tumor differentiation        | [49]       |

Table 1: Effects of PPARγ expression/activation in different human tumors.

PPARγ is expressed in a variety of tumors and its role in cancer formation/progression has been controversial for long time [45–52]. In vitro studies have shown that PPARγ activation results in growth arrest of epithelial-derived cancer cell lines, including those from thyroid, lung, prostate, breast, pituitary, and colon [53–58]. Consistently, some PPARγ downstream targets, such as the CDK inhibitors p15, p21, and p27, are induced determining a cell cycle block...
Table 2: Effects of TZD administration on human cell lines derived from different tumors.

| Cell types          | Observed effects                      | References |
|---------------------|---------------------------------------|------------|
| Colorectal cancer   | Growth arrest, differentiation, apoptosis | [39, 57, 67, 68, 70] |
| Thyroid carcinoma   | Growth arrest                          | [54]       |
| Prostate cancer     | Growth arrest                          | [55]       |
| Ependymoma          | Growth arrest                          | [39]       |
| Lung carcinoma      | Cell cycle arrest                      | [58, 62, 69, 76] |
| Breast cancer       | Cell cycle arrest                      | [56, 66]   |
| Hepatoma            | Cell cycle arrest                      | [59, 63]   |
| Neuroblastoma       | Increased proliferation                | [81]       |
| Pancreatic carcinoma| Cell cycle arrest                      | [60, 61]   |

The tumor suppressor gene, PTEN, is also upregulated upon PPARγ activation in different cell lines, inhibiting PI3-kinase and AKT phosphorylation, hence reducing cell migration and proliferation [61–64]. Tumor growth is also inhibited through the interference with the APC/β-catenin and COX-2/PGE2 signaling pathways, which are pivotal in colon carcinogenesis [8, 65]. PPARγ downregulates matrix metalloproteinase-7 (MMP-7) and induces MMP inhibitors expression, suppressing tumor cell invasion [66, 67]. In colon cancer and non-small-cell lung carcinoma cells, PPARγ induces the expression of the transcriptional repressors TSC22 and GADD153, respectively [68, 69]. To reinforce the anti-proliferative effects, PPARγ downregulates the anti-apoptotic protein Bcl-2 [70]. More recently, PPARγ has been endowed with an antiangiogenic activity through inhibition of VEGF and its receptors in different cells [71, 72]. As previously mentioned, PPARγ inhibits NFκB-mediated gene transcription. Constitutive activation of NFκB is frequently observed in solid tumors leading to overexpression of a variety of target genes that confer growth advantages and resistance to chemotherapy [73, 74]. Finally, PPARγ hampers the Epithelial–mesenchymal transition (EMT), a well-known process that allows cancer cells to acquire invasive ability, a prerequisite for metastasis formation. EMT is characterized by a reversible conversion of polarized epithelial cells into highly motile fibroblastoid cells accompanied by loss of cell–cell adhesion molecules, such as E-cadherin, downregulation of epithelial differentiation markers, and expression of mesenchymal markers such as vimentin and N-cadherin [75, 76]. PPARγ inhibits TGFβ-induced EMT in lung and pancreatic adenocarcinoma cell lines by antagonizing Smad3-dependent transcriptional activity. As a result, EMT, morphological changes, MMPs secretion, migration, and invasion are greatly diminished [76]. All together, these data strongly support a role for PPARγ as tumor suppressor; in contrast, a few studies have provided evidence that it acts as a tumor promoter [14, 64, 77, 78]. In line with this latter hypothesis, PPARγ expression has recently been found elevated at the mRNA and protein levels in chicken embryo fibroblasts (CEFs) transformed by the Ski oncogene. These cells, unlike most other oncogene-transformed cells, do not display the classical Warburg effect and have a reduced glucose utilization associated with increased fatty acids β-oxidation. PPARγ upregulation appears then to drive the oncogenic lipid metabolism required for high-rate cell proliferation and enhanced survival. PPARγ knocked-down by RNA interference reverses the expression of both PPARγ and its target genes [79]. Another study has showed that HER2-overexpressing breast cancer cells present an increased PPARγ expression that exacerbates tumor development as it fuels lipogenic enzymes reducing accumulated fatty acids toxicity. Her-2 transformed cells have adopted an oncogenic lipid metabolism that is instrumental in cell proliferation and survival. Her-2 overexpression significantly activates the MAPK pathway responsible for most of the effects observed. However, this pathway negatively regulates PPARγ, so trastuzumab administration not only reduces the levels of MAPK activity but also downregulates PPARγ; these beneficial effects appear more remarkable when combined with PPARγ agonists [80]. A more recent work, finally,
suggests for PPARγ a dual role as a tumor-promoting factor in neuroblastoma cells and as a tumor suppressor in breast cancer cells. In the former case, PPARγ induces cell growth \textit{in vitro} and tumor growth in mouse xenografts through the induction of inflammation and of NHE1, an oncogenic factor. Conversely, in the latter case, it inhibits NHE1 expression. These discordant results have been attributed to cell type-specific differences in the regulation of NHE1 and other target genes [81]. Collectively, the large wealth of data accumulated so far on the specific role that \textit{PPARG} plays in tumorigenesis supports a cell growth restraining function, hence a tumor suppressor activity.

Since PPARγ is expressed in differentiated epithelial colonic cells and in colorectal cancer (CRC), a specific role has been hypothesized in colon pathophysiology [38, 82]. CRC is one of the most frequent malignancies in western countries and a common cause of cancer-related death worldwide [83]. A great effort has, thus, been made to understand the molecular mechanisms through which \textit{PPARG} affects CRC progression. The lack of suitable cellular models...
to assess its role in normal colonic epithelial cells has made necessary to evaluate the effects of PPARy agonists in vivo. Indeed, the first two articles reported that administration of PPARy ligands increased the incidence of colon tumors in Apc+/Min mice [84, 85]. In contrast, PPARy produced no effects on tumor incidence in Apc/1638N and 1309 mice, using both genetic and pharmacological models [37, 86]. A more recent study has shown that pioglitazone, a TZD family member, suppresses colon tumor growth in Apc+/Min mice [87]. These contradictory observations on the Ppara role in tumorigenesis have apparently been resolved by more recent data obtained by a tissue-specific Ppara biallelic knockout in Apc+/Min mice. In this strain, an increased tumor incidence and tumor size is observed, consistent with the in vitro data obtained in human cancer cell lines: PPARy ligands inhibit cell growth even in the presence of APC mutations [88–91]. In azoxymethane (AOM)-treated rodents, the most widely used preclinical model of sporadic CRC in rodents, Ppara inhibits colon carcinogenesis [92–94]. In this system, TZDs act as potent suppressors of tumor formation. Of note, some of the effects attributed to TZDs can be due to PPARy-independent effects [95, 96]. A direct role of PPARy as tumor suppressor is confirmed by the observation that hemizygous Ppara colon-specific knockout mice display a significantly higher incidence of colon tumors following AOM treatment [97]. Epidemiological studies in humans have clearly established a link between chronic inflammatory conditions and tumor initiation. Inflammatory bowel diseases (IBD) are associated with a higher risk of development of a CRC subtype known as colitis-associated cancer (CAC). In these cases, tumor promotion is mainly due to the presence of leukocyte infiltration and inflammatory mediators. Consistently, administration of nonsteroidal anti-inflammatory drugs to IBD patients results in reduced CRC development [98]. In mouse models, PPARy activation by selective agonists has been shown to attenuate the severity of chemically induced IBD also in colon-specific Ppara-null mice [99]. This is due to activation of PPARy in macrophages, central orchestrators of the inflammatory response in IBD. In agreement, Ppara ablation in these cells increases the susceptibility to chemically induced colitis, suggesting that PPARy can inhibit the inflammation-associated tumor initiation acting both in epithelial cells and in macrophages [99, 100]. In spite of the results obtained in murine models, evidence of PPARy involvement in human colon carcinogenesis is still circumstantial. PPARy is expressed at high levels in about 60% of sporadic human CRCs. Specific loss-of-function mutations have been reported in 8% of primary CRCs, an observation not confirmed in a subsequent study, in which these mutations were defined as “very rare events” [101, 102]. Increasing evidence suggests that PPARy activity is attenuated during the transition from adenoma to carcinoma, likely explaining why PPARy agonists can block the early stages of tumorigenesis. In fact, they inhibit aberrant crypt focus (ACF) formation but have little or no effect on advanced tumor stages [37]. PPARy attenuation may involve, at least in part, its phosphorylation operated by the mitogen activated kinase ERK 1/2, and its ligand-independent SUMOylation, two posttranslational modifications that negatively regulate PPARy activity [103, 104]. Loss-of-function mutations and the reduced activity due to posttranslational modifications, however, do not fully explain the low PPARy expression found in 35% of sporadic CRCs [105]. Interestingly, these levels have been associated with a more aggressive course, EMT activation, and patients’ worse prognosis, indicating that PPARy can be considered an independent prognostic factor [105, 106]. Other mechanisms should be suggested to explain the low PPARy levels observed.

4. Epigenetics and Cancer

It is well accepted that genetic mutations as well as epigenetic modifications contribute to tumor establishment and/or progression. “Epigenetics” indicates changes in chromatin structure that result in different gene expression patterns without alterations of the primary DNA sequence and regardless of heritability [107]. In contrast to genetic lesions, epigenetic variations are reversible and involve changes in DNA methylation, histone posttranslational modifications, and expression of noncoding RNAs (ncRNAs) [108]. Over 25 years ago, Feinberg and Vogelstein found an extensive loss of DNA methylation in colon cancer cells. This global hypomethylation has been associated with increased genome instability and overexpression of a variety of genes implicated in CRC pathogenesis [109]. More recent findings indicate that the association of a global hypomethylation with a discrete hypermethylation at promoter regions of specific genes involved in cell-cycle regulation, DNA repair, apoptosis, angiogenesis, adhesion, and invasion is a common event in tumorigenesis [110]. Promoter hypermethylation at MLH1, APC, RB1, VHL, MGMT, GSTP1, and BRCA1 represents paradigmatic cancer-related epigenetic silencing events [111]. Available data support the notion that epigenetic abnormalities arise in the earliest steps of tumor development. Aberrant methylation patterns are, in fact, already recognized in preneoplastic lesions such as dysplastic ACFs and hyperplastic polyps and are considered as a risk factor for the development of CIMP-positive CRCs [110–114].

Four DNA methyltransferases (DNMTs): DNMT1, DNMT3A, DNMT3B, and DNMT3L establish and regulate the global patterns of DNA methylation in healthy and tumor cells. DNMT1 associates with S-phase replication foci and acts primarily as a maintenance methyltransferase. DNMT3A and DNMT3B are essential for de novo methylation during embryonic development. Finally, DNMT3L forms a complex with DNMT3A and DNMT3B in embryonic stem cells and stimulates their activity [115–117]. Deregulation of DNMTs expression contributes to tumorigenesis, conferring an aberrant methylation pattern and causing tumor suppressor genes promoter methylation [118, 119]. DNA methylation alone, however, is not sufficient to repress gene transcription. A complex and intertwined set of posttranslational modifications of the core histone tails dynamically imparts either repressive or activating transcriptional signals, following the so-called histone code. These marks, and the cellular machinery regulating them, are also frequently disrupted in cancer [119].
Methylation at lysine 9 of histone H3 (H3K9) is one of the most studied histone modifications, and SUV39H1 was initially recognized as endowed with H3K9 histone methyltransferase (HMTs) activity. Recently, more H3K9 specific methyltransferases have been identified: SUV39H2, G9a, SETDB1, and EuHMase1, each of them able to cause different methylation states. G9a is mainly responsible for SUV39H1 mono- and dimethylation primarily found in euchromatin, while SUV39H1 directs the trimethylation of the same residue found in facultative or constitutive heterochromatin [119–122]. SUV39H1, in addition, is overexpressed in tumors [122].

Trimethylation at lysine 27 of H3 (H3K27me3) is a distinct histone modification primarily involved in the maintenance of gene silencing. Enhancer of zeste 2 (EZH2) is the unique histone methyltransferase with H3K27 substrate specificity. EZH2, together with EED and SUZ12, forms the polycomb group (PcG) repression complex 2 (PRC2) and initiates gene silencing by trimethylating H3K27 and recruiting the PRC1 complex. This latter includes BMI-1, RING1, HPC, and HPH and its binding to the DNA blocks the recruitment of activating transcriptional factors, such as SWI/SNF, and prevents initiation of transcription by RNA polymerase II [123].

Acetylation of lysine 27 of H3 and lysine 16 of H4 (H3K27ac and H4K16ac), in contrast, characterize the promoter regions of actively transcribed genes. Also di- and trimethylation of lysine 4 of H3 histone (H3K4me2/me3) are active marks, at odds with other methylated residues. H3K4 methylation seems to protect gene promoters from de novo DNA methylation in somatic cells, preventing the recruitment of heterochromatin-inducing proteins [124]. These “activating” histone marks are carried out by a series of histone acetyltransferases (HATs), among which the best known is CBP/p300 and the associated pCAF, and by specific K4H3 methyltransferases as MLL and ASH [113, 125, 126]. The “active” histone modifications are frequently altered in cancer cells, in line with the fact that histone deacetylases (HDACs), that remove histone acetylation, are overexpressed or mutated in different tumor types [127]. DNA methylation and histone modifications are strictly interconnected. Genome-wide DNA methylation profiles, in fact, suggest that DNA methylation is better correlated with histone methylation patterns than with the underlying genome sequence context. Specifically, DNA methylation is correlated with the presence of H3K9 methylation and the absence of H3K4 methylation [128, 129]. The relationship between DNA methylation- and EZH2-dependent (PRC2-dependent) silencing has not been completely elucidated. In prostate cancer cells, these two epigenetic modifications act in an independent and inverse mode; conversely, in CRC cell lines DNA methylation is accompanied by H3K27me3 formation [123, 130]. This discrepancy is explained by tissue- and cancer-specific differences related to activation of specific silencing pathways [123]. Cooperation of DNA methylation and histone modifications requires proteins that directly readout the DNA methylation pattern and recruit the histone modifying enzymes or vice versa. In some cases, the DNMTs, such as DNMT3b, directly interface with the histone methylases SUV39H1, EZH2, and G9a [128–130]. Accessory proteins are, in other cases, required for recruiting histone-modifying enzymes and/or DNMTs. Methyl-DNA binding proteins (MBP) form a protein family whose members recognize 5’meC, and some of them are endowed with lysine methyltransferase activity to repress transcription through heterochromatin formation [131]. Me Cp2 binds a single methylated CpG dinucleotide and recruits HDACs to silence transcription via histone deacetylation; moreover, it plays a role in tumorigenesis and has been shown to target several genes in different tumors in vivo [132, 133]. Kaiso, another zinc finger domain containing protein, is capable of binding not only a pair of methylated CpG dinucleotides but also unmethylated DNA. Given Kaiso’s ability to repress transcription at both methylated and unmethylated promoters, it is currently difficult to assess how important its mCpG binding role is in cancer [132]. Finally, the SRA-domain containing proteins, UHRF1 and UHRF2, recruit HDAC1 and methylate tumor suppressor gene promoters. UHRF1 has affinity for hemimethylated DNA and recruits DNMT1 to ensure the epigenetic inheritance of DNA methylation and maintenance of histone marks [131, 133]. Additionally, UHRF1 seems to play a role in the DNA damage response and is able to recruit the de novo DNMTs on gene-specific promoters [131, 133–135]. Finally, in addition to proteins, also RNAs can modulate chromatin structure. Long non-coding and micro RNAs are widely transcribed in the genome, and their roles are only at the beginning to be understood. Recent studies suggest that some of them can function as an interface between DNA and specific chromatin remodelling activities. However, their involvement in human cancers has not been fully elucidated yet [136, 137].

In this scenario, the CIMP (CpG island methylator phenotype) positive tumors that account for approximately 20% of CRCs deserve special attention [114]. They are characterized by promoter hypermethylation of specific genes, defined “CIMP markers”, and by microsatellite instability (MSI). This condition of genomic instability is in contrast with CIN-positive (chromosomal instability) tumors characterized by a different genomic status that drives the adenoma/carcinoma differentiation. Interestingly, MeCP2 is associated with a positive (chromosomal instability) tumors characterized by a different genomic status that drives the adenoma/carcinoma differentiation. Interestingly, MeCP2 is associated with a

5. PPARG Epigenetic Regulation

Consistent with the results reported above, research efforts have been made to investigate the mechanisms that regulate PPARG expression. At the moment, we have only a limited knowledge of the transcription factors and mechanisms that modulate PPARG. Pparg2 promoter demethylation has recently been shown to correlate with 3T3-L1 adipocyte differentiation. Interestingly, MeCP2 is associated with a
Partially adapted from reference [39].

A repressive complex containing UHRF1, MeCP2, DNMT3b, HDAC1, SUV39H1 and EZH2 is recruited inducing transcription repression. PPARG has been identified. Active histone marks, such as H3K9ac, H3K4me3 and H4K16ac are present together with the RNA polymerase II. (b) The partially methylated core promoter is bound by still unknown transcriptional factors, among which only the zinc-finger protein ZAC is identified UHRF1 as a mediator of PPARG expression. The histone methyltransferase SUV39H1 is also a constituent of this multiprotein repression complex (Figure 3). UHRF1, DNMT3b, and SUV39H1 are frequently upregulated in CRC, and this condition is associated with UHRF1 activation, especially in advanced tumor stages, suggests that they are part of a more complex regulatory circuit. In agreement with these results, a very recent methylation profile carried out in supratentorial and spinal ependymomas suggests that epigenetic silencing of tumor suppressor genes, including PPARG, is crucial in the development of these neoplasms [143].

6. Concluding Remarks

The recent achievements in the understanding of the tumorigenic mechanisms have clearly demonstrated that epigenetic deregulation can result in altered gene function and malignant cellular transformation. Genomic instability is emerging as a hallmark of cancer and the rapidly evolving field of cancer epigenetics has led to the identification and characterization of the CIMP phenotype with the provocative hypothesis of epigenomic instability. In this context, it has been suggested that an incorrect association between nuclear receptors and the epigenetic machinery may contribute to tumor development. Among nuclear silencing and methylated Pparg2 promoter in undifferentiated preadipocytes [138, 139]. In line with this, MeCP2 is recruited onto the Pparg1 promoter along with HP1, H3K9me3, and EZH2-dependent H3K27me3, driving its epigenetic silencing in hepatic stellate cells (HSCs). This event is pivotal in inducing HSCs transdifferentiation into myofibroblasts leading to a fibrotic liver [39, 140]. More recent studies from our laboratory have addressed the epigenetic regulation of PPARG transcription in human colon cancer [141]. The analysis of CRC cell lines has demonstrated that PPARG promoter hypermethylation correlates with reduced gene transcription, presence of H3K9me3, and H3K27me3 and concomitant recruitment of HDAC1, MeCP2, and EZH2. Conversely, epigenetic treatment with 5-aza-2’-deoxycytidine and trichostatin A induces PPARG reexpression associated with recruitment of active histone marks, RNApol-II, and the transcriptional activator ZAC. Remarkably, the same promoter region that is methylated in PPARG-negative cells is methylated also in 80% of our PPARG-negative CRCs. These data provide the first direct evidence that PPARG is epigenetically downregulated in human CRC, and this condition is associated with poor patients’ prognosis [141]. In addition, we have identified UHRF1 as a mediator of PPARG silencing. The UHRF1 ability is to keep promoters in a hypermethylated state, together with the possibility of mediating de novo methylation, gives this factor an important role in cancer development through silencing tumor suppressor genes. UHRF1 upregulation is inversely correlated with PPARG expression in an advanced tumor stages CRC subgroup [142]. Consistently, UHRF1 knockdown in vitro reactivates PPARG, while UHRF1 overexpression induces its repression due to recruitment of MeCP2, EZH2, and DNMT3b. The histone methyltransferase SUV39H1 is also a constituent of this multiprotein repression complex (Figure 3). UHRF1, DNMT3b, and SUV39H1 are frequently upregulated in CRC, and our studies confirm their role in the epigenetic repression of protein-coding genes [118, 122, 141, 142]. Altogether, these results suggest that epigenetic mechanisms play a crucial role in PPARG derepression and tumor development. PPARG epigenetic silencing might, thus, be a critical and common step of the tumorigenic process. The association with UHRF1 activation, especially in advanced tumor stages, suggests that they are part of a more complex regulatory circuit. In agreement with these results, a very recent methylation profile carried out in supratentorial and spinal ependymomas suggests that epigenetic silencing of tumor suppressor genes, including PPARG, is crucial in the development of these neoplasms [143].
receptors, PPARs are pivotal in several biological processes. Specifically, PPARγ has been shown to protect against tumor progression. Epigenetic silencing is emerging as an unprecedented level of complexity of PPARγ expression. Deciphering the precise code that dictates this event and the players involved is one of the major present efforts. This approach will provide useful insight as to how epigenetic events at PPARγ are related with the genomic instability status in CRC. It will also address the unanswered question as to whether PPARγ epigenetic deregulation contributes to the establishment of “precancerous lesions” or very early cancer developmental stages. Lastly, it will provide the basis for designing more efficient epigenetic drugs affecting cancer initiation/progression. PPARγ can then be viewed as a target of novel therapeutic strategies.

Authors’ Contribution
L. Sabatino and A. Fucci contributed equally to the work.

Acknowledgment
This work has partially been supported by a grant from Associazione Italiana per la Lotta ai Linfomi e Leucemie (AIL) to VC.

References
[1] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004.
[2] A. Schweitzer, S. K. Knauer, and R. H. Stauber, “Nuclear receptors in head and neck cancer: current knowledge and perspectives,” International Journal of Cancer, vol. 126, no. 4, pp. 801–809, 2010.
[3] M. Lehrke and M. A. Lazar, “The many faces of PPARy,” Cell, vol. 123, no. 6, pp. 993–999, 2005.
[4] I. Issmann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[5] S. A. Kliewer, B. M. Forman, B. Blumberg et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994.
[6] D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995.
[7] S. R. Pyper, N. Viswakarma, S. Yu, and J. K. Reddy, “PPARα: energy combustion, hypolipidemia, inflammation and cancer,” Nuclear Receptor Signaling, vol. 8, p. 6002, 2010.
[8] D. Wang and R. N. DuBois, “Peroxisome proliferator-activated receptors and progression of colorectal cancer,” PPAR Research, vol. 2008, Article ID 931074, 7 pages, 2008.
[9] R. Scatena, P. Bottoni, and B. Giardina, “Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key?” PPAR Research, vol. 2008, Article ID 256251, 10 pages, 2008.
[10] B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.
[11] S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARs in health and disease,” Nature, vol. 405, no. 6785, pp. 421–424, 2000.
[12] C. H. Lee, P. Olson, and R. M. Evans, “Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors,” Endocrinology, vol. 144, no. 6, pp. 2201–2207, 2003.
[13] R. M. Evans, G. D. Barish, and Y. X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004.
[14] Z. Nahle, “PPAR trilogy from metabolism to cancer,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 7, no. 4, pp. 397–402, 2004.
[15] L. Michalik, J. Auwerx, J. P. Berger et al., “International union of pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006.
[16] L. Michalik and W. Wahli, “Involvement of PPAR nuclear receptors in tissue injury and wound repair,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006.
[17] M. Grabacka, W. Placha, P. M. Plonka et al., “Inhibition of melanoma metastases by fenofibrate,” Archives of Dermatological Research, vol. 296, no. 2, pp. 54–58, 2004.
[18] M. Grabacka, P. M. Plonka, K. Urbanska, and K. Reiss, “Peroxisome proliferator-Activated receptor α activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt,” Clinical Cancer Research, vol. 12, no. 10, pp. 3028–3036, 2006.
[19] N. Strakova, J. Ehrmann, J. Bartos, J. Malikova, J. Dolezeil, and Z. Kolar, “Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of gibal brain tumors,” Neoplasma, vol. 52, no. 2, pp. 126–136, 2005.
[20] R. Grau, C. Punzón, M. Fresno, and M. A. Iniguez, “Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1,” Biochemical Journal, vol. 395, no. 1, pp. 81–88, 2006.
[21] F. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gonzalez, and J. M. Peters, “Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis,” Nature Medicine, vol. 10, no. 5, pp. 481–483, 2004.
[22] K. R. Reed, O. J. Sansom, A. J. Hayes et al., “PPARδ status and Apc-mediated tumourigenesis in the mouse intestine,” Oncogene, vol. 23, no. 55, pp. 8992–8996, 2004.
[23] R. L. Stephen, M. C. U. Gustafsson, M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004.
[24] B. Glinghammar, J. Skogsgberg, A. Hamsten, and E. Ehrenborg, “PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells,” Biochemical and Biophysical Research Communications, vol. 308, no. 2, pp. 361–368, 2003.
[25] L. Fajas, J. C. Fruchart, and J. Auwerx, “PPARY3 mRNA: a distinct PPARY mRNA subtype transcribed from an independent promotor,” FEBS Letters, vol. 438, no. 1–2, pp. 55–60, 1998.
[26] K. Al-Shali, H. Cao, N. Knows, A. R. Hermus, C. J. Tack, and R. A. Hegele, “A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006.
of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5655–5660, 2004.

[27] Y. Zhu, K. Alves, Q. Huang, M. S. Rao, and J. K. Reddy, “Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver,” Journal of Biological Chemistry, vol. 268, no. 36, pp. 26817–26820, 1993.

[28] A. Meirhaeghe and P. Amouyel, “Impact of genetic variation of PPARY in humans,” Molecular Genetics and Metabolism, vol. 83, no. 1–2, pp. 93–102, 2004.

[29] P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARY2: tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994.

[30] S. Hummasti and P. Tontonoz, “The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis,” Molecular Endocrinology, vol. 20, no. 6, pp. 1261–1275, 2006.

[31] D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi, “The transactivating function of peroxisome proliferator-activated receptor γ is negatively regulated by SUMO conjugation in the amino-terminal domain,” Genes to Cells, vol. 9, no. 11, pp. 1017–1029, 2004.

[32] J. P. Renaud and D. Moras, “Structural studies on nuclear receptors,” Cellular and Molecular Life Sciences, vol. 57, no. 12, pp. 1748–1769, 2000.

[33] A. Yessoufou and W. Wahli, “Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels,” Swiss Medical Weekly, vol. 140, p. 13071, 2010.

[34] R. Mukherjee, L. Jow, G. E. Croston, and J. R. Paterniti Jr, “Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists,” Journal of Biological Chemistry, vol. 272, no. 12, pp. 8071–8076, 1997.

[35] P. Wang, J. Renes, F. Bouwman, A. Bunschoten, E. Mariman, and J. Keijer, “Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression,” Diabetologia, vol. 50, no. 3, pp. 654–665, 2007.

[36] L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARα gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997.

[37] E. A. Thompson, “PPARγ physiology and pathology in gastrointestinal epithelial cells,” Molecules and Cells, vol. 24, no. 2, pp. 167–176, 2007.

[38] S. Drori, G. D. Girmun, L. Tou et al., “Hic-5 regulates an epithelial program mediated by PPARγ,” Genes and Development, vol. 19, no. 3, pp. 362–375, 2005.

[39] J. Mann, D. C. K. Chu, A. Maxwell et al., “MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis,” Gastroenterology, vol. 138, no. 2, pp. 705–e4, 2010.

[40] J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARβ/δ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003.

[41] M. Ricote and C. K. Glass, “PPARs and molecular mechanisms of transrepression,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 926–935, 2007.

[42] M. Li, G. Pascual, and C. K. Glass, “Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene,” Molecular and Cellular Biology, vol. 20, no. 13, pp. 4699–4707, 2000.

[43] C. G. Su, X. Wen, S. T. Bailey et al., “A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response,” Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999.

[44] G. Pascual, A. L. Fong, S. Ogawa et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ,” Nature, vol. 437, no. 7039, pp. 759–763, 2005.

[45] M. Matsuyama and R. Yoshimura, “A novel approach to anti-cancer therapies: peroxisome proliferator activator receptor-γ as a new target therapy in the treatment of human urological cancer,” Endocrine, Metabolic and Immune Disorders, vol. 9, no. 1, pp. 76–83, 2009.

[46] C. M. Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function implications for regulating steroidogenesis, differentiation, and tissue remodeling,” Reproductive Biology and Endocrinology, vol. 3, p. 41, 2005.

[47] H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391–397, 2003.

[48] I. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006.

[49] G. D. Demetri, C. D. M. Fletcher, E. Mueller et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999.

[50] E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPARγ,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998.

[51] R. G. Mehta, E. Williamson, M. K. Patel, and H. P. Koefler, “A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions,” Journal of the National Cancer Institute, vol. 92, no. 5, pp. 418–423, 2000.

[52] I. Cellai, G. Petrangolini, M. Tortoreto et al., “In vivo effects of rosiglitazone in a human neuroblastoma xenograft,” British Journal of Cancer, vol. 102, no. 4, pp. 685–692, 2010.

[53] A. P. Heaney, M. Fernando, and S. Melmed, “PPAR-γ receptor ligands: novel therapy for pituitary adenomas,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1381–1388, 2003.

[54] K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, “Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2170–2177, 2001.

[55] T. Kubota, K. Koshizuka, E. A. Williamson et al., “Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,” Cancer Research, vol. 58, no. 15, pp. 3344–3352, 1998.

[56] F. Yin, S. Wakino, Z. Liu et al., “Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle
regulators,” Biochemical and Biophysical Research Communications, vol. 286, no. 5, pp. 916–922, 2001.

[57] M. Kato, T. Kusumi, S. Tsuchida, M. Tanaka, M. Sasaki, and H. Kudo, “Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 2, pp. 73–79, 2004.

[58] Y. Tsunbuchi, H. Sano, Y. Kawahito et al., “Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis,” Biochemical and Biophysical Research Communications, vol. 270, no. 2, pp. 400–405, 2000.

[59] H. Y. Lau, “Apoptosis induced by activation of peroxisome proliferator-activated receptor-γ mediates a SknC oncocytic-induced cell-cycle arrest in human hepatoma cell lines,” Hepatology, vol. 35, no. 5, pp. 1087–1097, 2001.

[60] W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells,” Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000.

[61] B. Farrow and B. M. Evers, “Activation of PPARy increases PTEN expression in pancreatic cancer cells,” Biochemical and Biophysical Research Communications, vol. 301, no. 1, pp. 50–53, 2003.

[62] S. Y. Lee, G. Y. Hur, K. H. Jung et al., “PPAR-γ agonist increases gefitinib’s antitumor activity through PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2006.

[63] W. Zhang, N. Wu, Z. Li, L. Wang, J. Jin, and X. L. Zha, “PPARγ activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404,” Cancer Biology and Therapy, vol. 5, no. 8, pp. 1008–1014, 2006.

[64] K. Tachibana, D. Yamasaki, K. Ishitomo, and T. Doi, “The role of PPARs in cancer,” PPAR Research, vol. 2008, Article ID 102737, 2008.

[65] H. Inoue, T. Tanabe, and K. Umesono, “Feedback control of cyclooxygenase-2 expression through PPARγ,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028–28032, 2000.

[66] H. Liu, C. Zang, M. H. Fenner, K. Possinger, and E. Elstner, “PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro,” Breast Cancer Research and Treatment, vol. 79, no. 1, pp. 63–74, 2003.

[67] D. Shen, C. Deng, and M. Zhang, “Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells,” Postgraduate Medical Journal, vol. 83, no. 980, pp. 414–419, 2007.

[68] R. A. Gupta, P. Sarraf, J. A. Brockman et al., “Peroxisome proliferator-activated receptor γ and transforming growth factor-β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22,” Journal of Biological Chemistry, vol. 278, no. 9, pp. 7431–7438, 2003.

[69] T. Satoh, M. Toyoda, H. Hoshino et al., “Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung cancer cells,” Oncogene, vol. 21, no. 14, pp. 2171–2180, 2002.

[70] G. G. Chen, J. F. Y. Lee, S. H. Wang, U. P. F. Chan, P. C. Ip, and W. Y. Lau, “Apoptosis induced by activation of peroxisome proliferator-activated receptor-γ is associated with Bel-2 and NF-κB in human colon cancer,” Life Sciences, vol. 70, no. 22, pp. 2631–2646, 2002.

[71] X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.

[72] D. Panigrahy, S. Singer, L. Q. Shen et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002.

[73] M. Kojima, T. Morisaki, N. Sasaki et al., “Increased nuclear factor-κB activation in human colorectal carcinoma and its correlation with tumor progression,” Anticancer Research, vol. 24, no. 2, pp. 675–681, 2004.

[74] C. Zeng, J. H. Xiao, M. J. Chang, and J. L. Wang, “Beneficial effects of THSG on acetic acid-induced experimental colitis: involvement of upregulation of PPARγ and inhibition of the NF-κB inflammatory pathway,” Molecules, vol. 16, no. 10, pp. 8552–8568, 2011.

[75] L. Pelletier, S. Rebouissou, D. Vignjevic, P. Bioulac-Sage, and J. Zucman-Rossi, “HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cells,” BMC Cancer, vol. 11, p. 427, 2011.

[76] A. K. Reka, H. Kurapati, V. R. Narala et al., “Peroxisome proliferator-activated receptor-g activation inhibits tumor metastasis by antagonizing smad3-mediated epithelial-mesenchymal transition,” Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3221–3232, 2010.

[77] G. Kristiansen, J. Jacob, A. C. Buckendahl et al., “Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times,” Clinical Cancer Research, vol. 12, no. 21, pp. 6444–6451, 2006.

[78] S. Tyagi, P. Gupta, A. Saini, C. Kaushal, and S. Sharma, “The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases,” Journal of Advanced Pharmaceutical Technology and Research, vol. 2, no. 4, pp. 236–240, 2011.

[79] F. Ye, H. Lemieux, C. L. Hoppel et al., “Peroxisome proliferator-activated receptor γ (PPARγ) mediates a Ski oncogene-induced shift from glycolysis to oxidative energy metabolism,” Journal of Biological Chemistry, vol. 286, no. 46, pp. 40013–40024, 2011.

[80] J. A. Menendez, “Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 381–391, 2010.

[81] J. Lee, A. Drakaki, D. Iliopoulos, and K. Struhl, “MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells,” Oncogene. In press.

[82] W. Su, C. R. Bush, B. M. Necula et al., “Differential expression, distribution, and function of PPARγ in the proximal and distal colon,” Physiological Genomics, vol. 30, no. 3, pp. 342–353, 2007.

[83] J. Wei, M. Koch, J. Debus, T. Hohler, P. R. Galle, and M. W. Buchler, “Colorectal cancer,” Lancet, vol. 365, no. 9454, pp. 153–165, 2005.

[84] E. Saez, P. Tontonoz, M. C. Nelson et al., “Activators of the nuclear receptor PPARγ enhance colon polyp formation,” Nature Medicine, vol. 4, no. 9, pp. 1058–1061, 1998.

[85] M. Lefebvre, B. Paulweber, L. Fajas et al., “Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998.

[86] N. Nito, M. Takahashi, T. Kitamura et al., “Concomitant suppression of hyperlipidemia and intestinal polypl...
formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands, “Cancer Research,” vol. 63, no. 18, pp. 6090–6095, 2003.

[87] N. Niho, M. Takahashi, Y. Shoji et al., “Dose-dependent suppression of hyperlipidemia and intestinal polyph formation in Min mice by pioglitazone, a PPARγ ligand,” “Cancer Science,” vol. 94, no. 11, pp. 960–964, 2003.

[88] C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier, “Intestinal-specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice,” “International Journal of Cancer,” vol. 119, no. 10, pp. 2339–2346, 2006.

[89] C. R. Bush, J. M. Havens, B. M. Necela et al., “Functional genomics analysis reveals cross-talk between peroxisome proliferator-activated receptor-γ chemokines and calcium signaling in human colorectal cancer cells,” Journal of Biological Chemistry,” vol. 282, no. 32, pp. 23387–23401, 2007.

[90] R. A. Gupta, P. Sarraf, E. Mueller et al., “Peroxisome proliferator-activated receptor-γ mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms,” Journal of Biological Chemistry,” vol. 278, no. 25, pp. 22669–22677, 2003.

[91] T. Yoshizumi, T. Ohta, I. Ninomiya et al., “Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects,” “International Journal of Oncology,” vol. 25, no. 3, pp. 631–639, 2004.

[92] H. Kohno, S. Yoshitani, S. Takashima et al., “Troglitazone, a ligand for peroxisome proliferator-activated receptor-γ, inhibits chemically-induced aberrant crypt foci in rats,” Japanese Journal of Cancer Research,” vol. 92, no. 4, pp. 396–403, 2001.

[93] T. Tanaka, H. Kohno, S. I. Yoshitani et al., “Ligands for peroxisome proliferator-activated receptors α and β inhibit chemically induced colitis and formation of aberrant crypt foci in rats,” Cancer Research,” vol. 61, no. 6, pp. 2424–2428, 2001.

[94] E. Osawa, A. Nakajima, K. Wada et al., “Peroxisome proliferator-activated receptor-γ ligands suppress colon carcinogenesis induced by azoxymethane in mice,” Gastroenterology,” vol. 124, no. 2, pp. 361–367, 2003.

[95] S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor-γ and mediated by inhibition of translation initiation,” Cancer Research,” vol. 61, no. 16, pp. 6213–6218, 2001.

[96] M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters, “The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR),” Toxicological Sciences,” vol. 90, no. 2, pp. 269–295, 2006.

[97] G. D. Girman, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPARγ,” Proceedings of the National Academy of Sciences of the United States of America,” vol. 99, no. 21, pp. 13771–13776, 2002.

[98] F. Balkwill, K. A. Charles, and A. Mantovani, “Smoldering and polarized inflammation in the initiation and promotion of malignant disease,” Cancer Cell,” vol. 7, no. 3, pp. 211–217, 2005.

[99] S. Danese, A. Malesci, and S. Vetran, “Colitis-associated cancer: the dark side of inflammatory bowel disease,” Gut,” vol. 60, no. 12, pp. 1609–1610, 2011.

[100] Y. M. Shah, K. Morimura, and F. J. Gonzalez, “Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitis,” American Journal of Physiology,” vol. 292, no. 2, pp. G657–G666, 2007.

[101] P. Sarraf, E. Mueller, W. M. Smith et al., “Loss-of-function mutations in PPARγ associated with human colon cancer,” Molecular Cell,” vol. 3, no. 6, pp. 799–804, 1999.

[102] T. Ikezoe, C. W. Miller, S. Kawano et al., “Mutational analysis of the peroxisome proliferator-activated receptor γ in human malignancies,” Cancer Research,” vol. 61, no. 13, pp. 5307–5310, 2001.

[103] E. Burgermeister and R. Seger, “MAPK kinases as nucleocytoplasmic shuttles for PPARγ,” Cell Cycle,” vol. 6, no. 13, pp. 1539–1548, 2007.

[104] T. M. Garcia-Bates, G. M. Lehmann, P. J. Simpson-Haidaris, S. H. Bernstein, P. J. Sime, and R. P. Phipps, “Role of peroxisome proliferator-activated receptor γ and its ligands in the treatment of hematological malignancies,” PPAR Research,” vol. 2008, Article ID 834612, 18 pages, 2008.

[105] M. Pancione, N. Forte, L. Sabatino et al., “Reduced beta-catenin and peroxisome proliferator-activated receptor-γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2 and patient outcome,” Human Pathology,” vol. 40, no. 5, pp. 714–725, 2009.

[106] S. Ogino, K. Shima, Y. Baba et al., “Colorectal cancer expression of peroxisome proliferator-activated receptor γ (PPARG, PPARγ) is associated with good prognosis,” Gastroenterology,” vol. 136, no. 4, pp. 1242–1250, 2009.

[107] M. Berdasco and M. Esteller, “Aberrant epigenetic landscape in cancer: how cellular identity goes awry,” Developmental Cell,” vol. 19, no. 5, pp. 698–711, 2010.

[108] V. K. Rakyan, T. A. Down, D. J. Balding, and S. Beck, “Epigenome-wide association studies for common human diseases,” Nature Reviews Genetics,” vol. 12, no. 8, pp. 529–541, 2011.

[109] B. Vogelstein, E. R. Fearon, S. R. Hamilton et al., “Genetic alterations during colorectal-tumor development,” New England Journal of Medicine,” vol. 319, no. 9, pp. 525–532, 1988.

[110] F. J. Carmona and M. Esteller, “Epigenomics of human colon cancer,” Mutation Research,” vol. 693, no. 1–2, pp. 53–60, 2010.

[111] M. Esteller, “Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes,” European Journal of Cancer,” vol. 36, no. 18, pp. 2294–2300, 2000.

[112] A. P. Feinberg and B. Tycko, “The history of cancer epigenetics,” Nature Reviews Cancer,” vol. 4, no. 2, pp. 143–153, 2004.

[113] R. Venkatachalam, M. J. Ligtenberg, N. Hoogerbrugge, D. R. de Bruijin, R. P. Kuiper, and A. Geurts van Kessel, “The epigenetics of (hereditary) colorectal cancer,” Cancer Genetics and Cytogenetics,” vol. 203, no. 1, pp. 1–6, 2010.

[114] J. P. Issa, “Colon cancer: it’s CIN or CIMP,” Clinical Cancer Research,” vol. 14, no. 19, pp. 5939–5940, 2008.

[115] B. Jin, B. Yao, J. L. Li et al., “DMNT1 and DMNT3B modulate distinct polycomb-mediated histone modifications in colon cancer,” Cancer Research,” vol. 69, no. 18, pp. 7412–7421, 2009.

[116] H. Gowher, C. J. Stockdale, R. Goyal, H. Ferreira, T. Owen-Hughes, and A. Jeltsch, “De novo methylation of nucleosomal DNA by the mammalian Dnmt1 and Dnmt3A DNA methyltransferases,” Biochemistry,” vol. 44, no. 29, pp. 9899–9904, 2005.

[117] K. Nosho, K. Shima, N. Irahara et al., “DMNT3B expression might contribute to CpG island methylator phenotype in colorectal cancer,” Clinical Cancer Research,” vol. 15, no. 11, pp. 3663–3671, 2009.

[118] H. G. Linhart, H. Lin, Y. Yamada et al., “Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation"
and transcriptional silencing,” *Genes and Development*, vol. 21, no. 23, pp. 3110–3122, 2007.

[119] R. A. Varier and H. T. M. Timmers, “Histone lysine methylation and demethylation pathways in cancer,” *Biochimica et Biophysica Acta*, vol. 1815, no. 1, pp. 75–89, 2011.

[120] B. Lehnertz, Y. Ueda, A. A. H. A. Derijck et al., “Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin,” *Current Biology*, vol. 13, no. 14, pp. 1192–1200, 2003.

[121] M. Tachibana, J. Ueda, M. Fukuda et al., “Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9,” *Genes and Development*, vol. 19, no. 7, pp. 815–826, 2005.

[122] H. Özdağ, A. E. Teschendorff, A. A. Ahmed et al., “Differential expression of selected histone modifier genes in human solid cancers,” *BMC Genomics*, vol. 7, p. 90, 2006.

[123] Y. Kondo, L. Shen, A. S. Cheng et al., “Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation,” *Nature Genetics*, vol. 40, no. 6, pp. 741–750, 2008.

[124] A. Shilatifard, “Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation,” *Current Opinion in Cell Biology*, vol. 20, no. 3, pp. 341–348, 2008.

[125] A. Portela and M. Esteller, “Epigenetic modifications and human disease,” *Nature Biotechnology*, vol. 28, no. 10, pp. 1057–1068, 2010.

[126] T. Vaissière, C. Sawan, and Z. Herceg, “Epigenetic interplay between histone modifications and DNA methylation in gene silencing,” *Mutation Research*, vol. 659, no. 1-2, pp. 40–48, 2008.

[127] A. Meissner, T. S. Mikkelson, H. Gu et al., “Genome-scale DNA methylation maps of pluripotent and differentiated cells,” *Nature*, vol. 454, no. 7205, pp. 766–770, 2008.

[128] E. Viré, C. Brenner, R. Deplus et al., “The Polycomb group protein EZH2 directly controls DNA methylation,” *Nature*, vol. 439, no. 7078, pp. 871–874, 2006.

[129] P. O. Estève, G. C. Hang, A. Smallwood et al., “Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication,” *Genes and Development*, vol. 20, no. 22, pp. 3089–3103, 2006.

[130] S. Epsteyn-Litman, N. Feldman, M. Abu-Ramaleh et al., “De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes,” *Nature Structural and Molecular Biology*, vol. 15, no. 11, pp. 1176–1183, 2008.

[131] L. Parry and A. R. Clarke, “The roles of the methyl-CpG binding proteins in cancer,” *Genes and Cancer*, vol. 2, no. 6, pp. 618–630, 2011.

[132] X. Nan, H. H. Ng, C. A. Johnson et al., “Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex,” *Nature*, vol. 393, no. 6683, pp. 386–389, 1998.

[133] A. Rottach, C. Frauer, G. Pichler, I. M. Bonapace, F. Spada, and H. Leonhardt, “The multi-domain protein Np95 connects DNA methylation and histone modification,” *Nucleic Acids Research*, vol. 38, no. 6, Article ID gkp1152, pp. 1796–1804, 2009.

[134] A. L. Tien, S. Senbanerjee, A. Kulkarni et al., “UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis,” *Biochemical Journal*, vol. 435, no. 1, pp. 175–185, 2011.

[135] D. Meilingner, K. Fellinger, S. Bultmann et al., “Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cells,” *EMBO Reports*, vol. 10, no. 11, pp. 1259–1264, 2009.

[136] R. Kogo, T. Shimamura, K. Mimori et al., “Long non-coding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers,” *Cancer Research*, vol. 71, no. 20, pp. 6320–6326, 2011.

[137] E. A. Gibb, C. J. Brown, and W. L. Lam, “The functional role of long non-coding RNA in human carcinomas,” *Molecular Cancer*, vol. 10, p. 38, 2011.

[138] K. Fujiki, F. Kano, K. Shiota, and M. Murata, “Expression of the peroxisome proliferator activated receptor γ gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes,” *BMC Biology*, vol. 7, p. 38, 2009.

[139] N. Salma, H. Xiao, E. Mueller, and A. N. Imbalzano, “Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor γ nuclear hormone receptor;” *Molecular and Cellular Biology*, vol. 24, no. 11, pp. 4651–4663, 2004.

[140] J. Mann, F. Oakley, F. Akibeoye, A. Elsharkawy, A. W. Thorne, and D. A. Mann, “Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis,” *Cell Death and Differentiation*, vol. 14, no. 2, pp. 275–285, 2007.

[141] M. Pancione, L. Sabatino, A. Fucci et al., “Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients’ outcome,” *PLoS ONE*, vol. 5, no. 12, Article ID e14229, 2010.

[142] L. Sabatino, A. Fucci, M. Pancione et al., “UHRF1 coordinates peroxisome proliferator activated receptor γ (PPARG) epigenetic silencing and mediates colorectal cancer progression,” *Oncogene*. In press.

[143] H. A. Rogers, J. P. Kilday, C. Mayne et al., “Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death,” *Acta Neuropathologica*, vol. 123, no. 5, pp. 711–725, 2012.